Clinical efficacy and safety of flumatinib versus dasatinib combined with multi-drug chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

Qian Liu, Tie Rong Bian, Zhi Yuan Li, Hong Yun Xing
{"title":"Clinical efficacy and safety of flumatinib versus dasatinib combined with multi-drug chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.","authors":"Qian Liu, Tie Rong Bian, Zhi Yuan Li, Hong Yun Xing","doi":"10.1016/j.htct.2023.12.005","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Flumatinib, a highly selective ABL kinase inhibitor, exhibits stronger inhibition of intracellular BCR-ABL tyrosine kinase activity, compared to Imatinib. However, there is limited research comparing the real-world efficacy and safety of flumatinib and dasatinib in patients with Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).</p><p><strong>Objective: </strong>Investigating the differences in therapeutic efficacy and safety between flumatinib and dasatinib in combination with multi-drug chemotherapy for the treatment of newly diagnosed Ph+ ALL.</p><p><strong>Method: </strong>In this study, we assessed 43 patients with newly diagnosed Ph+ ALL (20 in the flumatinib group, 23 in the dasatinib group).</p><p><strong>Results: </strong>There were no significant differences in gender, age, fusion gene type, initial blood routine, bone marrow blast cell ratio or chromosome karyotype between the two groups. Within 1 month, there were no significant differences in the complete response (CR), major molecular response (MMR) or minimal residual disease (MRD) negativity rate between the flumatinib and dasatinib groups. Similarly, within 3 months, there were no significant differences in CR or MMR rates between the two groups. However, the rates of complete molecular response (CMR) and MRD negativity within 3 months were significantly higher in the flumatinib group, compared to the dasatinib group (P < 0.05). Additionally, the flumatinib group exhibited fewer adverse reactions compared to the dasatinib group.</p><p><strong>Conclusion: </strong>These findings suggest that flumatinib is a safe and effective tyrosine kinase inhibitor (TKI) for achieving CMR and MRD negativity in patients with Ph+ ALL, as supported by this small series of patients.</p>","PeriodicalId":94026,"journal":{"name":"Hematology, transfusion and cell therapy","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematology, transfusion and cell therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.htct.2023.12.005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Flumatinib, a highly selective ABL kinase inhibitor, exhibits stronger inhibition of intracellular BCR-ABL tyrosine kinase activity, compared to Imatinib. However, there is limited research comparing the real-world efficacy and safety of flumatinib and dasatinib in patients with Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).

Objective: Investigating the differences in therapeutic efficacy and safety between flumatinib and dasatinib in combination with multi-drug chemotherapy for the treatment of newly diagnosed Ph+ ALL.

Method: In this study, we assessed 43 patients with newly diagnosed Ph+ ALL (20 in the flumatinib group, 23 in the dasatinib group).

Results: There were no significant differences in gender, age, fusion gene type, initial blood routine, bone marrow blast cell ratio or chromosome karyotype between the two groups. Within 1 month, there were no significant differences in the complete response (CR), major molecular response (MMR) or minimal residual disease (MRD) negativity rate between the flumatinib and dasatinib groups. Similarly, within 3 months, there were no significant differences in CR or MMR rates between the two groups. However, the rates of complete molecular response (CMR) and MRD negativity within 3 months were significantly higher in the flumatinib group, compared to the dasatinib group (P < 0.05). Additionally, the flumatinib group exhibited fewer adverse reactions compared to the dasatinib group.

Conclusion: These findings suggest that flumatinib is a safe and effective tyrosine kinase inhibitor (TKI) for achieving CMR and MRD negativity in patients with Ph+ ALL, as supported by this small series of patients.

费城阳性急性淋巴细胞白血病成人患者服用氟马替尼与达沙替尼联合多种药物化疗的临床疗效和安全性。
简介氟马替尼是一种高选择性ABL激酶抑制剂,与伊马替尼相比,它对细胞内BCR-ABL酪氨酸激酶活性的抑制作用更强。然而,在费城阳性急性淋巴细胞白血病(Ph+ ALL)患者中,对氟马替尼和达沙替尼的实际疗效和安全性进行比较的研究十分有限:调查氟马替尼和达沙替尼联合多种药物化疗治疗新诊断的Ph+ ALL的疗效和安全性差异:在这项研究中,我们评估了43例新诊断的Ph+ ALL患者(氟马替尼组20例,达沙替尼组23例):结果:两组患者在性别、年龄、融合基因类型、初始血常规、骨髓造血细胞比率和染色体核型方面无明显差异。1个月内,氟马替尼组和达沙替尼组的完全应答率(CR)、主要分子应答率(MMR)和最小残留病(MRD)阴性率无明显差异。同样,在3个月内,两组的CR或MMR率也无明显差异。然而,与达沙替尼组相比,氟马替尼组在3个月内的完全分子反应(CMR)率和MRD阴性率明显更高(P < 0.05)。此外,与达沙替尼组相比,氟马替尼组的不良反应更少:结论:这些研究结果表明,氟马替尼是一种安全有效的酪氨酸激酶抑制剂(TKI),可使Ph+ ALL患者获得CMR和MRD阴性,这一点也得到了该小样本患者的支持。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信